New research suggests that patients who stop using popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Published data in a major health publication demonstrates that while obese individuals frequently drop substantial amounts of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing such treatments must be aware of the risk of quick rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment mass within about one and a half years.
Comparing Therapies
The analysis, which reviewed dozens of trials involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with conventional dieting.
Scientists emphasize that people who shed pounds through dieting usually have a slower creep back—approximately 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Doctors suggest the way of the injections explains the accelerated weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' means hunger is uncontrolled, making overeating much more probable."
A Chronic Disease?
Health authorities advise the injections for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Professionals say that, given the likelihood of relapse, the therapy might need to be life-long.
This opinion is supported by pharmaceutical companies, who say that the results "emphasize the chronic character of excess weight," comparing it to managing conditions like high blood pressure.
Patient Accounts
Users who have discontinued the jabs explain a sudden return of cravings.
"I experienced something that goes on and you're instantly ravenous," recalled one woman.
This challenge is compounded if patients have not adopted sustainable dietary or behavioural changes during therapy.
Significant Adoption
Recent estimates suggest that a significant number of people in the UK have tried these injections in the past year, with interest continuing to grow.
- Adoption is greater among women compared to males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than public health services.
Finally, experts stress that while GLP-1 drugs are potent agents for weight loss, they are not a permanent cure and long-term success likely depends on combined lifestyle management.
